Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service
NMD Pharma Nears Validation For ClC-1 Inhibition With Lead Program In Myasthenia Gravis :: Scrip
Thomas Holm Pedersen - Roller i dansk erhvervsliv
NMD Pharma A/S | LinkedIn
NMD Pharma Raises €35 Million in a new Financing — NMD Pharma
NMD Pharma A/S | LinkedIn
NMD Pharma raises €35m to expand pipeline - European Pharmaceutical Manufacturer
Thomas Holm Pedersen on LinkedIn: Happy to share that NMD was awarded the Startup of the Year 2022 at Aarhus…
Other news — News — NMD Pharma
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma expands its US presence — NMD Pharma
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Thomas Pedersen email address & phone number | NMD Pharma A/S CEO contact information - RocketReach
Jeito Capital Becomes Key Investor in NMD Pharma as Part of a €35 Million New Financing | Business Wire
NMD Pharma Raises €35M Financing - FinSMEs
NMD Pharma A/S | LinkedIn
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma - PIR International
NMD Pharma (@NMDPharma) / Twitter
NMD Pharma cleared for spinal muscular atrophy trial
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma gets green light to proceed with neuromuscular target — MedWatch
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma - PIR International
Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service
NMD Pharma Raises €35 Million in a new Financing
NMD Pharma begins first clinical trial: "Our entire team can be enormously proud" — MedWatch
